Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Uniphar reports first-half growth across its divisions
(Sharecast News) - International diversified healthcare service provider Uniphar reported a solid set of first-half financial results on Tuesday, with notable growth across all of its divisions. The AIM-traded company's revenue increased 10.3% to €1.37bn, while gross profit rose 9.9% to €206.7m, driven by strong performances in its Pharma, Supply Chain & Retail, and Medtech divisions.
EBITDA grew 6.3% to €55.9m, reflecting the execution of its strategic initiatives and continued innovation.
The firm's Pharma division led the growth, with a 20.5% increase in gross profit, 20.2% of which was organic, underscoring the strength of its 'On Demand; business and pharma services.
Its Supply Chain & Retail division also performed well, posting an 8.1% increase in gross profit, supported by robust market demand and a strong customer service offering.
Medtech saw 3.4% growth in gross profit, all organic, despite strong comparators from the previous year.
Uniphar said its gross profit margin remained steady at 15.1%, while it maintained a strong cash flow performance, with a free cash flow conversion rate of 144%.
Net bank debt decreased to €143.6m from €149.9m at the end of 2023, reflecting a leverage ratio of 1.5x.
The group's strong balance sheet, including a €400m revolving credit facility and an additional uncommitted accordion facility of €150m provided significant financial flexibility.
Uniphar also highlighted recent strategic and operational progress, including the successful integration of the McCauleys Pharmacy Group, which enhanced its retail pharmacy offering.
Additionally, Uniphar said it was advancing its strategic capital expenditure on a state-of-the-art distribution facility in Ireland, aimed at doubling capacity and supporting the growth of its Supply Chain & Retail division and global pharma platform.
Looking ahead, Uniphar expected continued organic gross profit growth across all divisions in line with medium-term targets, adding that it was well-positioned to meet market expectations for the full year.
The board declared an interim dividend of 0.67 euro cents per share, a 5% increase from the prior year.
It added that sustainability remained a key focus, with the company making progress on its sustainability goals, including validated targets to reduce absolute scope one and two emissions by at least 50% by 2030.
"Uniphar has delivered a strong first half, with gross profit growth of almost 10% year-on-year," said chief executive officer Ger Rabbette.
"We are seeing the benefit of the hard work we have put in recently to build the foundations for the next stage of growth."
Rabbette said the strategic investments the firm was making in infrastructure and IT would further improve its ability to generate organic growth, and give Uniphar a stronger platform for integrating and achieving synergies from new acquisitions.
"We are confident that we will achieve our ambitious target of €200m EBITDA in the medium-term."
At 0942 BST, shares in Uniphar were down 0.69% at 226.43p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.